Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) 419 released the annual report for 2021, and the company achieved an operating revenue of 4.063 billion yuan, an increase of 53.48% over the previous year; The net profit attributable to the parent company was 634 million yuan, a year-on-year increase of 66.56%.
Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) is a well-known cdmo leading enterprise, which is mainly committed to providing cdmo one-stop services in R & D and production of innovative drugs for Chinese foreign innovative new drug companies and new drug R & D institutions, as well as providing process technology innovation and commercial production business for global chemical APIs and pharmaceutical intermediates. The company has successively won many honors, such as outstanding enterprise of green development in the pharmaceutical industry during the 13th five year plan, excellent enterprise of API export in 2021 China National Chemical Engineering Co.Ltd(601117) pharmaceutical industry and so on.
During the reporting period, the company’s API business further achieved a breakthrough upgrade, and the newly developed hypoglycemic products helped the customer’s preparation products to be approved for listing in Europe; At the same time, 17 generic drug preparation projects are in different research and development stages. Among them, the preparation product aed-02 sustained release tablet anda is still under FDA approval and submitted nmpa listing application in July 2021; The preparation product t2dm-02 sustained release tablets has obtained the nmpa listing application acceptance notice.
At present, Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) has built many leading technology platforms, including chiral catalysis technology, continuous technology application research platform, fluorine chemistry technology, enzyme catalysis technology, polypeptide technology research platform, etc. through a large number of project practice and successful technology transformation, it can effectively solve the process problems and technical challenges faced by customers and provide industry-leading technical solutions for customer projects.
In 2021, Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) continued to promote technology, equipment, service and management innovation to maintain efficient production and operation, and made every effort to build an excellent integrated CMO manufacturing platform for APIs and preparations to provide one-stop services for the sustainable supply of drugs to customers and patients. During the reporting period, the company undertook a number of high-quality CMO projects. The company acquired 100% equity of Hangzhou Zhulian Pharmaceutical Technology Co., Ltd. and 51% equity of Nanjing kangchuanji Pharmaceutical Co., Ltd. to rapidly improve the R & D strength of small molecule innovative drugs. Combined with the preparation commercial production base of Siwei pharmaceutical, a wholly-owned subsidiary of the company, the company fully has the one-stop service undertaking ability of small molecule API and preparation from CMC R & D to commercial production.
Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) while establishing closer cooperation with multinational pharmaceutical companies, the company has actively expanded business cooperation with local research and innovation pharmaceutical enterprises. The company’s business expansion ability has been continuously strengthened, the customer pool has expanded rapidly, and the number of customers worldwide has reached more than 800. The company has formed in-depth cooperation with international well-known pharmaceutical enterprises Novartis, Roche, zoetis, giead and the first three companies. In 2021, the company’s cdmo business revenue was 2.311 billion yuan and the business orders increased rapidly.
Under the trend of global outsourcing gradually shifting to China, Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) continued to promote the strategy of “deepening” key customers and “expanding” emerging customers, and the revenue increased steadily. The penetration rate of project pipelines between the company and large pharmaceutical companies in Europe and America has been further improved, the cooperation has been deepened, and the orders and projects have increased steadily; The listed projects served by the company continued to be stable and large-scale, and the project income increased steadily in the commercialization stage; As the company continues to strengthen the breadth and depth of cooperation in serving Chinese innovative drug companies, the number of new drug NDA projects of some customers continues to increase, and China’s business has entered a period of rapid growth.
